Navigating commissioning processes for new treatments and drugs
Route to market and key decision point advice key to successful entry and future commissioning
Key decision making oversight of all specialised commissioning England and rare diseases for UK (via Rare Diseases Advisory Group and Specialised Commissioning Oversight Group).
Discussions, negotiation oversight and strategy relating to Orphan drugs, new technologies and high cost drugs for England.
Intimate knowledge of NHS England pricing strategies, prioritisation and approach and how this is delivered locally by CCGs through to Acute Trusts.
Worked closely with Pharma, NICE, NIHR and government Life Sciences Agenda
Recent consulting projects –
For further information and details contact
Key decision making oversight of all specialised commissioning England and rare diseases for UK (via Rare Diseases Advisory Group and Specialised Commissioning Oversight Group).
Discussions, negotiation oversight and strategy relating to Orphan drugs, new technologies and high cost drugs for England.
Intimate knowledge of NHS England pricing strategies, prioritisation and approach and how this is delivered locally by CCGs through to Acute Trusts.
Worked closely with Pharma, NICE, NIHR and government Life Sciences Agenda
Recent consulting projects –
- Route to market and pricing strategy for rare disease orphan drugs
- Route to market and opportunities for new genetic treatments
- Strategic approach to new chelating agent
- Market and access opportunity for new Haemophila A treatment
- Current and future landscape for ER= Breast Cancer treatments (including SERDs)
- Access and reimbursement for Parkinson's Disease products
- Pre-financing round advice for new technology and on going advice
- Current and future landscape and best approach for new and innovative HIV treatments
- Current and future Alzheimers treatment options
- Opportunities in low, medium secure Mental Health Provision
- Approach to market and authorisation of immuno-oncology therapies
- Homecare and transformation of out-of-hospital care
- Approach to UK for new NASH therapy
- Opportunities and strategic approach to Mental Health Care
- Novel treatments and combination treatments for CML
For further information and details contact